1-5 of 5
Bie Verbist
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A - and NPM1 -altered leukemias

Min Chul Kwon, Jan Willem Thuring, Olivier Querolle, Xuedong Dai, Tinne Verhulst, Vineet Pande, Ann Marien, Dries Goffin, Daniela V. Wenge, Hong Yue, Jevon A. Cutler, Cyrus Jin, Florian Perner, Shanna M. Hogeling, Paul L. Shaffer, Frank Jacobs, Petra Vinken, Wei Cai, Vikki Keersmaekers, Filmon Eyassu, Balpreet Bhogal, Karin Verstraeten, Sara El Ashkar, Jennifer A. Perry, Prathiba Jayaguru, Laura Barreyro, Anna Kuchnio, Nicolas Darville, Daniel Krosky, Gregor Urbanietz, Bie Verbist, James P. Edwards, Glenn S. Cowley, Robert Kirkpatrick, Ruth Steele, Lucille Ferrante, Christina Guttke, Nikki Daskalakis, E. Christine Pietsch, David M. Wilson, Ricardo Attar, Yusri Elsayed, Eric S. Fischer, Jan Jacob Schuringa, Scott A. Armstrong, Kathryn Packman, Ulrike Philippar
Journal: Blood
Blood (2024) 144 (11): 1206–1220.
https://doi.org/10.1182/blood.2023022480
Published: 2024
Includes: Supplemental data
Journal Articles

Preclinical Efficacy of the Menin-KMT2A Inhibitor JNJ-75276617 in Combination with Venetoclax and Azacitidine in AML

Min Chul Kwon, Tinne Verhulst, Dries Goffin, Ann Marien, Bie Verbist, Christina Guttke, Jan Willem Thuring, Lucille Ferrante, Nikki Daskalakis, E. Christine Pietsch, Yusri Elsayed, Kathryn Packman, Ulrike Philippar
Journal: Blood
Blood (2023) 142 (Supplement 1): 4167.
https://doi.org/10.1182/blood-2023-186204
Published: 2023
Journal Articles

Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia

Min Chul Kwon, Olivier Querolle, Xuedong Dai, Jan Willem Thuring, Tinne Verhulst, Ann Marien, Dries Goffin, Wei Cai, Vikki Keersmaekers, Filmon Eyassu, Karin Verstraeten, Sara El Ashkar, Shanna M Hogeling, Frank Jacob, Petra Vinken, Nicolas Darville, Vineet Pande, Daniel Krosky, Gregor Urbanietz, Bie Verbist, Lucille A. Ferrante, Christina Diane Drenberg, David Wilson, Ricardo M. Attar, Jan Jacob Schuringa, Nikki Daskalakis, Kathryn Packman, Christine Pietsch, Yusri Elsayed, Ulrike Philippar
Journal: Blood
Blood (2022) 140 (Supplement 1): 5928–5929.
https://doi.org/10.1182/blood-2022-168921
Published: 2022
Journal Articles

Daratumumab depletes CD38 + immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof, Bie Verbist, Jaime Bald, Torben Plesner, Khaja Syed, Kevin Liu, Niels W. C. J. van de Donk, Brendan M. Weiss, Tahamtan Ahmadi, Henk M. Lokhorst, Tuna Mutis, A. Kate Sasser
Journal: Blood
Blood (2016) 128 (3): 384–394.
https://doi.org/10.1182/blood-2015-12-687749
Published: 2016
Includes: Supplemental data
Journal Articles

Immunomodulatory Effects and Adaptive Immune Response to Daratumumab in Multiple Myeloma

Jakub Krejcik, Tineke Casneuf, Inger Nijhof, Bie Verbist, Jaime Bald, Torben Plesner, MD, Kevin Liu, Niels W.C.J. van de Donk, Brendan Weiss, Tahamtan Ahmadi, Henk M. Lokhorst, Tuna Mutis, A. Kate Sasser
Journal: Blood
Blood (2015) 126 (23): 3037.
https://doi.org/10.1182/blood.V126.23.3037.3037
Published: 2015